The VEGF family in cancer and antibody-based strategies for their inhibition. - sprookjes - yvandenbroek - TriplyDB

The VEGF family in cancer and antibody-based strategies for their inhibition.

The VEGF family in cancer and antibody-based strategies for their inhibition.

http://www.wikidata.org/entity/Q33733437

about

Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features Mechanisms of action of therapeutic antibodies for cancer Antibody Therapies in Cancer.Vascular endothelial growth factor-D modulates oxidant-antioxidant balance of human vascular endothelial cells Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors.Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60.Clinical advances in the development of novel VEGFR2 inhibitors.Monitoring therapeutic monoclonal antibodies in brain tumor.Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity.Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia.Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.Identification and characterization of VEGF-A-responsive neutrophils expressing CD49d, VEGFR1, and CXCR4 in mice and humans.A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation Conjugation of Polymer-Coated Gold Nanoparticles with Antibodies-Synthesis and Characterization.Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer.Gastrointestinal cancer cells treatment with bevacizumab activates a VEGF autoregulatory mechanism involving telomerase catalytic subunit hTERT via PI3K-AKT, HIF-1α and VEGF receptors PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab The natural compound chebulagic acid inhibits vascular endothelial growth factor A mediated regulation of endothelial cell functions.Glioma stem cells and immunotherapy for the treatment of malignant gliomas.Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors.Hemocoagulase atrox reduces vascular modeling in rabbit carotid artery adventitia Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis.Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.Platelet-lymphocyte ratio acts as an indicator of poor prognosis in patients with breast cancer.Pathobiology of colorectal cancer hepatic metastases with an emphasis on prognostic factors.Meeting the biologic challenge of colorectal metastases.Immunotherapy and lung cancer: current developments and novel targeted therapies.Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.Population Pharmacokinetic Meta-Analysis of Ramucirumab in Cancer Patients.Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.Role of FGF10 on tumorigenesis by MS-K.Identification and in vitro characterization of phage-displayed VHHs targeting VEGF.Immunomodulatory Nanomedicine.Sindbis Virus-Pseudotyped Lentiviral Vectors Carrying VEGFR2-Specific Nanobody for Potential Transductional Targeting of Tumor Vasculature.MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy.Abnormalities in alternative splicing of angiogenesis-related genes and their role in HIV-related cancers.Intravitreal aflibercept for neovascular age-related macular degeneration.Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization.VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug.Beyond the Matrix: The Many Non-ECM Ligands for Integrins.

P2860

Q26776198-D4E6ABA4-6057-47EB-971A-B031BCB8DB22 Q28385366-F0269DA3-6201-462C-9EAD-DD1773BE2015 Q31104000-448C4C2D-DFC8-4F2A-807A-CAB55E96A4B3 Q33684215-371770B5-7464-42C6-AF10-653C002A54CE Q33793562-C7A3DD6B-23F2-4B21-AAA9-CD20E0F13EB4 Q33858304-C98FA072-FB72-4581-9D16-0075B3F7A286 Q34658366-CBA65964-CF5F-4344-8058-156220A5D56F Q35498835-EDB6A185-6FBC-4B8F-92EF-D843CE49C718 Q35525772-401AA98B-9CBF-4EDA-A00F-8F625AE3CEA9 Q35625070-DAD34DD4-DB47-4D48-AF45-7D6184AA9881 Q35918945-C71BFC23-9125-417C-9470-D51CC2BE0E60 Q36193194-18AD994F-31B7-4944-B201-102C78B89878 Q36216092-103F5E9D-4661-45C7-A3F9-18FFAC695DBA Q36324205-328731D1-7EDA-43EC-9B69-405527456F52 Q36333751-6BB7F68D-DB91-4DB0-BD40-6F47BA2EF360 Q36395933-F4F221AC-494E-4C8E-A58E-76954EF686F8 Q36535436-BB2A3E22-0443-4C1D-A1BC-7549B1F9B6F9 Q36761223-D9A04354-BFFD-4851-AB28-1A1D579CF8AB Q36898699-AA5D0822-2E80-480A-91C2-0B66DCEE82E6 Q37136650-92021F14-BE88-4789-817D-8C88B15C14E1 Q37277754-6A33518B-1E20-4924-81A7-CC01CD48B960 Q37688967-75742E83-81D4-4EE3-8652-8E8543135065 Q37696220-5B3BCE80-D868-42DF-9E2D-5CB41E6EB2BC Q37702039-7F39F159-C2C6-4118-A26D-D457F6A1C452 Q37821837-925B5BDB-FE3E-4368-B5AF-EC8E0A81275F Q38051068-2759387F-2677-4833-B4BE-67F859D94019 Q38286376-C4438B0E-0343-4258-93A4-63E33D11C14B Q38388551-6872DE0F-788A-45D7-9681-4195EBFAA72F Q38612237-DCF1684E-E1F6-4011-A53F-518691E16277 Q39004424-072C802C-562F-461D-9E05-ECCA23F22361 Q39045204-76E2AED6-52F7-4E8D-BE94-450DC0F360CF Q39051064-B8CB001F-4AC5-4591-9E37-60192C255E7C Q39224331-7A522B5A-5C0D-44DF-9320-0FCC6D885551 Q39372488-181B031D-5CB9-4D5C-8ED4-A9BEFF3D2F9D Q39390383-78660DD4-78C6-4651-AD52-5E7EE7E34BBC Q39426973-3D53A61A-2E6E-42A4-9F1F-F600173D24A7 Q39466620-8B774EEF-AEB6-466F-A5A9-91BBE03FA540 Q40422133-F5D2995A-C1E3-46AE-B588-F3DB61806B32 Q41186469-EE34E3A3-D09F-4147-BEEE-9994566A2452 Q47546891-617B54FF-FBAC-4ABB-852A-BF599F8ADE23

P2860

The VEGF family in cancer and antibody-based strategies for their inhibition.

http://www.wikidata.org/entity/Q33733437

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

The VEGF family in cancer and antibody-based strategies for their inhibition.

@ast

The VEGF family in cancer and antibody-based strategies for their inhibition.

@en

type

label

The VEGF family in cancer and antibody-based strategies for their inhibition.

@ast

The VEGF family in cancer and antibody-based strategies for their inhibition.

@en

prefLabel

The VEGF family in cancer and antibody-based strategies for their inhibition.

@ast

The VEGF family in cancer and antibody-based strategies for their inhibition.

@en

P1433

Q33733437-324A5FA7-1695-42EE-9220-372EEC845A5D

P1476

Q33733437-C1C469DF-BB28-433F-BC5B-15F0AC4B9618

P2093

Q33733437-15D7D9EF-34C2-48EE-A3FB-CCF27BE4C8DA

Q33733437-22E6938A-BB3F-406D-9E94-6235603365E5

P2860

Q33733437-02488B3F-5B9F-4412-90EC-8887CD7D08B3

Q33733437-02757699-2161-431B-8932-E8C49E90E9F3

Q33733437-036F5C82-AF63-4DDA-98A3-FD1A0623DD37

Q33733437-03CBA87E-6261-44DD-AB4C-74F49BE9C295

Q33733437-03CE022C-EEA6-43EA-8EA3-BE7C9AE5BA88

Q33733437-042E172C-FB75-4705-8BCB-5A0CC96E2BE4

Q33733437-04B27CEA-1DE2-47B9-B23F-4F080F48EA84

Q33733437-08CDDAD4-6379-440B-AA1E-76883FF97D7E

Q33733437-0C4750AA-B225-42D1-9F23-D3835F2C8757

Q33733437-140D7465-1087-4E3E-9889-E4CC0011F530

P304

Q33733437-5EA3AAF1-DB6C-4BA2-8FD3-66DB506E953E

P31

Q33733437-71AE39F4-73C1-4EFA-9931-3F20AF3BCCF7

P356

Q33733437-10108A09-626E-41B6-895E-7CC0C238E376

P433

Q33733437-DC93806C-96F0-4E69-BD09-378948DF1E91

P478

Q33733437-B114F4EB-0FC4-4046-8F68-0795259A64F8

P577

Q33733437-45E1D7CD-D3F6-4BB2-8E8E-7AAE1C3E383C

P5875

Q33733437-41A3EC19-74AD-4079-B225-2970ACD32F83

P698

Q33733437-20D6AC95-C6B5-4778-A7AE-C730E48E89D6

P921

Q33733437-236249B6-F19E-458D-B05E-CF446828814E

P932

Q33733437-A4306728-F33B-4526-B1E8-576841B15E03

P356

P1433

Monoclonal Antibodies

P1476

The VEGF family in cancer and antibody-based strategies for their inhibition.

@en

P2093

Laura A Sullivan

http://www.w3.org/2001/XMLSchema#string

Rolf A Brekken

http://www.w3.org/2001/XMLSchema#string

P2860

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

The Hallmarks of Cancer

A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family

Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1

Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform

Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor

Human FIGF: cloning, gene structure, and mapping to chromosome Xp22.1 between the PIGA and the GRPR genes

P304

165-175

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/MABS.2.2.11360

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41623147

http://www.w3.org/2001/XMLSchema#string

P698

20190566

http://www.w3.org/2001/XMLSchema#string

P921

P932

2840235

http://www.w3.org/2001/XMLSchema#string